NASDAQ$SLNO
Soleno Therapeutics Inc · Q3 2025 earnings
Q3 2025 earnings · · After market close · Investor relations
Briefing
Soleno Therapeutics reported Q3 2025 product revenue of $66.0M with net income of $26.0M.
Product revenue reached $66.0 million following VYKAT XR launch after FDA approval in March 2025, versus no product revenue a year ago. Net income was $26.0 million as the rare-disease commercial ramp accelerated.
- Q3 product revenue $66.0M (VYKAT XR launch).
- Net income $26.0M.
- First commercial quarter scale for VYKAT XR.
- Launch execution and payer access critical.
Headline financials
Revenue & EPS history
Soleno Therapeutics · Revenue · Quarterly
$66M
Forward guidance
The filing discusses Soleno Therapeutics's outlook, capital deployment, and key risks without relying solely on numeric EPS guidance.
Tailwinds
- Soleno Therapeutics cited execution on strategic priorities in the filing.
- Balance sheet and liquidity support continued operations.
Headwinds
- Macro, competitive, and cost pressures may affect margins.
- Segment mix and one-time items can affect comparability.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q3 2025
-1.8%
Avg return
Earnings day
-1.6%
Avg return
5 days after
-0.6%
Avg return
30 days after
38%
18 / 48 earnings
Positive
+15.2%
Q4 2014
Best reaction
-26.4%
Q3 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +0.0% | -0.0% | — | |
| Q4 2025 | -7.1% | -8.1% | -26.7% | |
| Q3 2025 | -26.4% | -27.5% | -19.5% | |
| Q2 2025 | -3.2% | +2.7% | -14.1% | |
| Q1 2025 | +2.2% | -0.3% | +1.1% | |
| Q4 2024 | -2.5% | +10.2% | +41.3% | |
| Q3 2024 | +1.3% | +4.9% | -12.8% | |
| Q2 2024 | -3.5% | +0.2% | +3.9% | |
| Q1 2024 | -2.7% | -6.0% | -1.5% | |
| Q4 2023 | -1.0% | -2.8% | -7.9% | |
| Q3 2023 | -5.1% | -4.8% | +60.1% | |
| Q2 2023 | +4.3% | -2.1% | -22.9% | |
| Q1 2023 | -3.6% | -1.2% | +42.9% | |
| Q4 2022 | +3.0% | +16.3% | +87.6% | |
| Q3 2022 | +2.9% | +5.2% | -6.2% | |
| Q2 2022 | +12.7% | +11.0% | -16.2% | |
| Q1 2022 | -6.5% | +10.5% | +12.1% | |
| Q4 2021 | -3.7% | +4.9% | -8.2% | |
| Q3 2021 | -0.8% | -1.9% | -21.4% | |
| Q2 2021 | +3.8% | +4.7% | -0.8% | |
| Q1 2021 | -7.8% | -6.1% | -1.7% | |
| Q4 2020 | +0.0% | -47.5% | -50.2% | |
| Q3 2020 | -4.0% | +3.5% | -6.5% | |
| Q2 2020 | +6.1% | +4.5% | +20.7% | |
| Q1 2020 | -5.0% | -3.2% | -48.2% | |
| Q4 2019 | +13.0% | +1.1% | -21.1% | |
| Q3 2019 | +10.7% | +6.4% | +34.3% | |
| Q2 2019 | -0.5% | +3.1% | -4.6% | |
| Q1 2019 | -4.1% | -4.1% | +41.2% | |
| Q4 2018 | -14.9% | -10.3% | -26.5% | |
| Q3 2018 | +1.0% | -4.3% | -22.6% | |
| Q2 2018 | -4.3% | -5.1% | -20.4% | |
| Q1 2018 | +3.1% | +8.6% | +29.8% | |
| Q4 2017 | -0.7% | +1.5% | -9.0% | |
| Q3 2017 | -13.6% | -22.7% | -17.9% | |
| Q2 2017 | +8.6% | -6.2% | +28.4% | |
| Q1 2017 | +7.2% | +1.4% | -14.5% | |
| Q4 2016 | +6.3% | +0.1% | -14.7% | |
| Q3 2016 | -0.8% | +0.0% | -17.5% | |
| Q2 2016 | -5.1% | -2.4% | +8.6% | |
| Q1 2016 | -4.3% | — | — | |
| Q4 2015 | -9.1% | — | — | |
| Q3 2015 | -3.7% | — | — | |
| Q2 2014 | -14.1% | — | — | |
| Q2 2015 | -14.2% | — | — | |
| Q1 2015 | -14.3% | — | — | |
| Q4 2014 | +15.2% | — | — | |
| Q3 2014 | +0.6% | — | — | |
| Q1 2014 | — | — | — | |
| Q4 2013 | — | — | — | |
| Q3 2013 | — | — | — | |
| Q2 2013 | — | — | — | |
| Q1 2013 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro